Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study

Clin Neuropharmacol. 2001 May-Jun;24(3):181-3. doi: 10.1097/00002826-200105000-00013.

Abstract

A prospective survey was performed to characterize the prevalence of sleep attacks and to evaluate precipitating factors in a group of 236 patients with idiopathic Parkinson's disease. Sleep attacks were reported by 72 patients (30.5%). Multivariate analysis showed a marked association between the occurrence of sudden sleep episodes and first autonomic failure, followed by treatment with ropinirole and bromocriptine. The present work underlines the major contributing role of autonomic failure followed by dopamine agonists in the occurrence of such an event. Because a relationship between sleep attacks and not only ropinirole but also bromocriptine treatment was described, the present work suggests that sleep attacks are a common side effect of all dopamine agonists.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / adverse effects*
  • Autonomic Nervous System Diseases / chemically induced
  • Disorders of Excessive Somnolence / chemically induced*
  • Disorders of Excessive Somnolence / epidemiology*
  • Humans
  • Male
  • Middle Aged
  • Odds Ratio
  • Parkinson Disease / drug therapy
  • Parkinson Disease / epidemiology
  • Pharmacoepidemiology
  • Pilot Projects

Substances

  • Antiparkinson Agents